APOA5

APOA5 Full Name

apolipoprotein A-V

APOA5 Introduction

APOA5 (apolipoprotein A5) is a key regulator of plasma triglyceride metabolism, belonging to the apolipoprotein gene cluster on chromosome 11q23.3 that also includes APOA1, APOC3, and APOA4. The gene encodes a small protein of 366 amino acids with a molecular weight of approximately 39 kDa that is primarily synthesized in the liver and secreted into the bloodstream, where it associates with high-density lipoproteins (HDL), very low-density lipoproteins (VLDL), and chylomicrons. Unlike other apolipoproteins that primarily function in lipoprotein structure or receptor recognition, APOA5 acts as a potent modulator of triglyceride homeostasis by enhancing the catabolism of triglyceride-rich lipoproteins and inhibiting their hepatic production. Even small changes in APOA5 expression have profound effects on plasma triglyceride levels, making it one of the most influential genetic determinants of hypertriglyceridemia in humans. Common polymorphisms in the APOA5 gene, particularly the APOA5 S19W (c.56C>G, p.Ser19Trp) variant, are strongly associated with elevated triglycerides and increased risk of cardiovascular disease, while rare loss-of-function mutations cause familial combined hyperlipidemia and severe hypertriglyceridemia.

Figure 1. Schematic structure of APOA5.

Gene Structure and Protein Architecture
The human APOA5 gene spans approximately 2.3 kb and contains 4 exons. The full-length protein consists of 366 amino acids and is significantly larger than other exchangeable apolipoproteins in the same cluster. Like other apolipoproteins, APOA5 contains multiple amphipathic alpha-helices that mediate lipid binding and lipoprotein association. The protein is organized into several functional domains. The N-terminal region contains a signal peptide (amino acids 1-22) that directs secretion, followed by a lipid-binding domain that mediates association with lipoproteins. The central region contains multiple amphipathic alpha-helices with positively charged residues on the polar face, which facilitate interaction with lipoprotein lipase (LPL) and heparan sulfate proteoglycans. The C-terminal region contains a proline-rich domain that is unique to APOA5 and may be involved in protein-protein interactions. APOA5 is glycosylated at Asn-256, and this glycosylation may influence its secretion and stability. Unlike APOA1, which is a major structural component of HDL, APOA5 circulates at very low concentrations (approximately 200-400 ng/mL in human plasma, compared to 1-2 g/L for APOA1). Despite its low abundance, APOA5 exerts powerful effects on triglyceride metabolism through multiple mechanisms.

Biological Functions in Triglyceride Metabolism
APOA5 lowers plasma triglyceride levels through at least three distinct but complementary mechanisms. First, APOA5 enhances the catabolism of triglyceride-rich lipoproteins (VLDL and chylomicrons) by promoting the activity of lipoprotein lipase (LPL), the rate-limiting enzyme for triglyceride hydrolysis. APOA5 binds directly to LPL and to the endothelial cell surface protein GPIHBP1 (glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1), which transports LPL to the capillary lumen. By stabilizing the LPL-GPIHBP1 complex, APOA5 increases the efficiency of triglyceride hydrolysis and the clearance of triglyceride-rich lipoprotein remnants. Second, APOA5 inhibits the hepatic production of VLDL triglycerides. It reduces the secretion of VLDL particles from hepatocytes by interfering with the assembly of VLDL in the endoplasmic reticulum and by promoting the intracellular degradation of newly synthesized apolipoprotein B (APOB). Third, APOA5 enhances the clearance of remnant lipoproteins by the liver through low-density lipoprotein receptor (LDLR) and LDLR-related protein 1 (LRP1), possibly by altering the conformation of APOB or by acting as a ligand for these receptors. APOA5 also interacts with the angiopoietin-like proteins ANGPTL3 and ANGPTL4, which are endogenous inhibitors of LPL. APOA5 antagonizes the inhibitory effects of ANGPTL3 and ANGPTL4 on LPL, further promoting triglyceride hydrolysis. In addition to its role in triglyceride metabolism, APOA5 influences cholesterol homeostasis, glucose metabolism, and inflammation, though these functions are less well characterized.

Alternate Names for APOA5

APOA5; apolipoprotein A-V; APOA V; RAP3; apo-AV; apolipoprotein A5; regeneration-associated protein 3; APOAV; FLJ97995; MGC126836; MGC126838;